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Abstract
Notch is a critical regulator of angiogenesis and arterial specification. We show that ectopic expression of activated
Notch1 induces endothelial morphogenesis in human umbilical vein endothelial cells (HUVEC) in a VEGFR-1-depen-
dent manner. Notch1-mediated upregulation of VEGFR-1 in HUVEC increased their responsiveness to the VEGFR-1
specific ligand, Placental Growth Factor (PlGF). In mice and human endothelial cells, inhibition of Notch signaling
resulted in decreased VEGFR-1 expression during VEGF-A-induced neovascularization. In summary, we show that
Notch1 plays a role in endothelial cells by regulating VEGFR-1, a function that may be important for physiological
and pathological angiogenesis.
Introduction
Vascular endothelial growth factor-A (VEGF-A) is
essential to the multistep process of vascular develop-
ment, and proper vessel formation in a variety of set-
tings is exquisitely sensitive to levels of VEGF-A [1-4].
VEGF-A signals through two receptor tyrosine kinases:
VEGFR-1 (flt1) and VEGFR-2 (flk1), while placenta
growth factor (PlGF) signals exclusively through
VEGFR-1. Both VEGF-A and PlGF induce endothelial
cell proliferation, survival, and migration [3,5,6]. The
role of VEGFR-1 in angiogenesis has largely been
defined in terms of its opposition to VEGFR-2. VEGFR-
2 is considered the primary VEGF-A receptor that
drives angiogenesis, while VEGFR-1 has high binding
affinity for VEGF-A but weak kinase activity. Thus,
VEGFR-1 is thought to function mainly as a decoy
receptor that sequesters VEGF-A [7-11]. This concept is
supported by analysis of mouse models where deletion
of flt1 led to vessel overgrowth and disruption of vascu-
lar patterning [12]. In addition, mice expressing a
mutant allele of flt1 that lacks the tyrosine kinase
domain (flt1TK-/-) did not exhibit the vascular patterning
defects seen in flt1-/-mice, suggesting that in embryonic
development, the kinase activity of VEGFR-1 was dis-
pensable and that its predominant function is via its
high affinity binding to VEGF-A [9]. Despite this, a posi-
tive function for VEGFR-1 in angiogenesis has been
demonstrated in a variety of settings. flt1TK-/- mice dis-
played defects in tumor vessel formation and metastasis
[13,14], and inhibition of VEGFR-1 led to defects in
neovascularization of the eye [15]. The signaling path-
ways that regulate VEGFR-1 expression in endothelial
cells remain unclear.
Notch, a receptor that functions in cell fate decisions,
has been shown to be downstream of VEGF-A in
endothelial sprouting [16,17] and arterial specification
[18,19]. The Notch proteins are highly conserved trans-
membrane receptors that are required for normal
embryonic development. In mammals, there are four
Notch proteins (Notch1-4) that, upon binding with one
of five ligands, termed Delta-like (Dll) and Jagged, are
subject to a series of proteolytic cleavages by ADAM
metalloproteases and gamma-secretase. Cleavage
releases the intracellular domain of the Notch receptor,
which translocates to the nucleus and functions as a
transcriptional activator in complex with the transcrip-
tion factors CSL (CBF1, Su(H), Lag-2), Mastermind, and
histone acetyltransferases. To date, the importance of
the Notch pathway in regulating endothelial cell
response to VEGF-A has been studied with respect to
its effect on VEGFR-2, as it has been shown that Delta-
like 4 (Dll4) signaling represses VEGFR-2 expression
[16,20,21]. Current models assert a role for Dll4 in
restricting sprouting angiogenesis [20,22-24], but have
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not identified the Notch receptors that are important for
this effect, or whether Notch signaling can function
positively in endothelial cell morphogenesis. In addition,
whether Notch signaling through a particular receptor
can regulate VEGFR-1 expression in endothelial cells
has not been defined.
Using ectopic expression as well as protein-based, and
pharmacological loss of Notch function, we show that
VEGFR-1 expression is downstream of Notch signaling
in endothelial cells. Furthermore, we define a positive
role for Notch signaling in VEGF-driven morphogenesis
of endothelial cells via promotion of cell extension
which we demonstrate requires upregulation of VEGFR-
1. Coincident with the Notch-mediated upregulation of
VEGFR-1, we report Notch signaling enhances endothe-
lial cell responsiveness to PlGF. Finally, in an assay of
VEGF-A induced dermal angiogenesis, we show that a
protein based Notch inhibitor, the Notch1 decoy, can
reduce VEGFR-1 levels in neovessels. Collectively, our
data define a role for Notch in mediating the response




ZD1893, PD166866, and SU5416 are from Eisai Co., Ltd.
Compound E was obtained from the Korean Research
Institute of Chemical Technology. PlGF was obtained
from Research Diagnostics Institute. N1IC [25], LacZ,
and VEGF-A constructs were engineered into pAdlox
vector and adenovirus stocks were produced [26].
Notch1 decoy has been described [27]. Briefly, the extra-
cellular domain of rat Notch1 (bp 241-4229, accession
no. X57405) was fused to human IgG Fc and engineered
into pAdlox vector (Ad-Notch1 decoy) and adenovirus
stocks generated.
Cell Culture, Adenoviral Infections, retroviral infections,
siRNA
HUVEC were isolated from human umbilical vein as
described [28] and cultured in complete medium (EGM-
2 Bullet kit, LONZA) on porcine type I collagen (Nitta
Gelatine). KP1/VEGF121 cells were provided by Eisai
Co., Ltd, [27] and maintained in RPMI 1640 containing
10% FBS. HUVEC were infected with Ad-LacZ, Ad-
N1IC, Ad-VEGF-A, Ad-GFP, or Ad-Notch1 decoy at a
MOI of 40. HUVEC were co-infected with Ad-LacZ and
Ad-Notch1 decoy at a MOI of 40 for each virus.
HUVEC infected with Ad-LacZ at a MOI of 80 served
as a control. Retroviral control and N1IC-expressing
HUVEC lines were generated as previously described
[29]. Control, VEGFR-1, and VEGFR-2 siRNA (Santa
Cruz) were introduced into HUVEC using Effectene
Reagent (Qiagen). Total RNA or cell lysate was har-
vested 48 hours after siRNA transfection.
RT-PCR
HUVEC were seeded on type I collagen gels two days
after adenoviral infection or retroviral infection and 5
days later total RNA was isolated with RNeasy mini kit
(Qiagen). First-strand cDNA was synthesized using
SuperScript First-Strand Synthesis System (Invitrogen).
For RT-PCR, primers were designed to recognize
human and mouse transcripts of VEGFR-1, VEGFR-2,
VEGF-A, PlGF, GAPDH and beta-actin, (primer
sequence available upon request). PCR used Platinum
Taq DNA polymerase (Invitrogen) and reactions per-
formed for 25 or 30 cycles. Reactions were performed in
triplicate.
Western Blotting
HUVEC were cultured on type I collagen gels for 5 days
in complete medium, then starved in serum free med-
ium for 48 hours and cell lysates were collected with
TENT lysis buffer. Western blots were performed using
antibodies against Flt1 (C-17, Santa Cruz), Flk1 (C-1158,
Santa Cruz), and alpha-tubulin (Sigma). To validate
Notch1 decoy secretion, serum-free medium from ade-
novirally transduced HUVEC was used for western blot
analysis using an antibody against the Fc tag (Pierce).
HUVEC Morphogenesis Assay
Adenovirus infections were performed two days before
seeding on porcine type I collagen, and HUVEC mor-
phogenesis was assessed by microscopy after 5 days, as
described [30]. Extensions were scored as number of
cells with single or multiple processes per 10× micro-
scopy field. Processes were defined as extensions at
acute angles to the cell body that alter normal HUVEC
morphology. For each experiment, at least five 10× fields
of cultures from each condition were scored. Kinase
inhibitors were added to the medium one hour after
HUVEC seeding, and PlGF was added at the time of
HUVEC seeding. For knockdown experiments, siRNA
was transfected two days after adenvoviral infection and
the cells were cultured for three days before assessment
of HUVEC with cellular extensions. Cell number was
measured using Cell Counting Kit-8 (Dojindo).
Mouse DAS Assay
The Dorsal Air Sac (DAS) assay was performed as
described [31]. Millipore chambers were packed with 5.0
× 106 KP1/VEGF121 cells that were transduced (60
MOI) with either Ad-GFP or Ad-Notch1 decoy and
transplanted into a DAS of C57BL/6 mice. Mice were
sacrificed four days after implantation and implants har-
vested and embedded in OCT. Each group consisted of
at 3-5 mice, and experiments done in triplicate.
Immunohistochemistry
5-μm serial sections of KP1/VEGF121 implants were
immunostained as described [32]. The following antibo-
dies were used: PECAM (553370, BD Pharmingen), Flt1
(AF417, R&D Systems), Flk1 (AF644, R&D Systems).
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Quantitative analysis of CD31, Flk1, and Flt1 immunos-
taining of skin was performed on serial sections using
an Eclipse E800 microscope and Nikon DXM 1200 cam-
era, with ImagePro Plus software (Silver Spring, MD).
Measurements were made in five different areas in each
sample at 20× magnification and average density ratio
was determined by dividing the area of specific staining
by the total area of the smooth muscle layer.
Flow Cytometry
2 × 105 HUVEC were seeded per well in a collagen-
coated 6-well plate. 24 hrs after seeding, cells were sti-
mulated with 50 ng/ml recombinant VEGF-A (R&D Sys-
tems) in complete medium, with or without 200 nM
Compound E (Korean Research Institute). DMSO was
used to treat control cells. 24 hours post-stimulation,
cells were harvested with cold PBS, washed, and incu-
bated with rabbit-anti VEGFR-1 (Santa Cruz) for 45
minutes at 4°C. After washing, cells were labeled with
anti-rabbit-APC (Jackson Immunoresearch) for 25 min-
utes at 4°C. Flow cytometry was performed and 10,000
cells per experimental group were counted using FACS-
Calibur and CellQuestPro acquisition software (BD
Biosciences).
Statistical Analysis
Data were expressed as mean plus or minus SEM. Sta-
tistical analysis was performed by 2-tailed student t test.
P value of less than 0.05 is indicated with ⋆, P value of
less than 0.02 is indicated with *. All data shown is
representative of at least 3 independent experiments.
Results
Notch signaling induced cellular extensions and VEGFR-1
expression in HUVEC
We investigated whether Notch1 signaling could affect
endothelial cell morphogenesis, as manifested by the
appearance of VEGF-A- or Notch-induced cellular
extensions from human umbilical vein endothelial cells
(HUVEC)[27,30]. HUVEC were transduced with an ade-
novirus expressing the intracellular domain of Notch1
(Ad-N1IC) or a control plasmid (Ad-LacZ), and seeded
on three-dimensional Type I collagen gels. The N1IC
construct encodes a constitutively active, gamma-secre-
tase cleavage-independent form of Notch1 [25]. Ad-
infected HUVEC were evaluated and scored for the
number of cells forming cellular extensions per field, as
well as for cell number, three days after seeding. We
found that Ad-N1IC HUVEC displayed an increase in
cellular extensions compared to Ad-LacZ cells (Figure
1A-B). Because HUVEC were cultured in the presence
of multiple growth factors, we determined if this effect
was due to signaling through a particular receptor using
specific small molecule inhibitors for FGFR, EGFR and
VEGFR. While inhibitors to fibroblast growth factor
receptor (FGFR) or epidermal growth factor receptor
(EGFR) did not inhibit extensions in Ad-N1IC HUVEC,
SU5416, an inhibitor of VEGFR-1 and VEGFR-2, sup-
pressed N1IC-induced extensions (Figure 1C-E). The
reduction in extensions seen with VEGFR inhibition was
accompanied by a 33% decrease in cell number (Figure
1F). However, the extension defect seen in cells treated
with SU5416 was more dramatic than the decrease in
cell number. Inhibition of N1IC-induced extensions in
HUVEC with SU5416 was dose-dependent (Figure 1G).
In endothelial cells, Notch signaling is known to down-
regulate VEGFR-2 expression, thus we hypothesized that
the Notch-induced extensions were mediated by
VEGFR-1 [20,29]. Consistent with this hypothesis, we
found that N1IC expression induced expression of
VEGFR-1 transcripts (Figure 1H) and protein (Figure
1I). We also observed that N1IC suppressed VEGFR-2
transcripts (Figure 1H), similar to previous publications
[20,24]. These data suggest that induction of extensions
in Ad-N1IC HUVEC is dependent on VEGFR-1, not
VEGFR-2.
Notch1-induced extensions in HUVEC is enhanced by
PlGF
Because ectopic expression of Notch1 induced VEGFR-
1, we hypothesized that these cells would exhibit
increased responsiveness to the PlGF. Ad-N1IC or con-
trol Ad-LacZ HUVEC were cultured on Type I collagen
gels in serum free medium, with or without 50 ng/ml
PlGF. While PlGF did not induce extensions in control
cells (Figure 2A-B), addition of PlGF to N1IC-expressing
HUVEC enhanced extensions (Figure 2C-D). Extensions
in N1IC-expressing HUVEC were generally one or two
processes from a single cell (Figure 2C, black arrow-
heads), while addition of PlGF led to a near threefold
increase in cells with more than two extensions (Figure
2D, open arrowheads, Figure 2E). Notch was found to
increase the levels of PlGF, but not VEGF-A transcripts
in HUVEC (Figure 2F), which may contribute to the
extensions induced in HUVEC expressing N1IC in the
absence of exogenous PlGF. Thus, while PlGF alone is
not sufficient to induce HUVEC morphogenesis, in the
context of activated Notch1 signaling, PlGF can enhance
extensions in these cells, likely due to increased expres-
sion of VEGFR-1.
Reduced VEGFR-1, but not VEGFR-2, inhibited Notch-
induced extensions in HUVEC
Though VEGFR-2 expression in endothelial cells is
downregulated by Notch signaling (Figure 1H), the pos-
sibility that cellular extensions in N1IC-expressing
HUVEC is the result of residual VEGFR-2 and that
enhanced extensions with PlGF is due to intermolecular
crosstalk between VEGFR-1 and VEGFR-2 [33,34],
could not be excluded. To examine these possibilities,
Ad-N1IC HUVEC were transfected with VEGFR-1,
VEGFR-2, or a control (CT) siRNA and cultured on
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collagen gels to determine the effect of decreased
expression of individual receptors on Notch-induced
extensions. Compared to Ad-N1IC HUVEC treated with
control siRNA, transcript and protein levels of VEGFR-1
in cells transfected with VEGFR-1 siRNA were reduced,
as shown by RT-PCR and western blot (Figure 3A).
VEGFR-2 expression was unaltered by the VEGFR-1
siRNA (Figure 3A, left). Similarly, VEGFR-2 siRNA was
specific for VEGFR-2, resulting in decreased transcripts
and protein expression, but VEGFR-2 siRNA did not
affect levels of VEGFR-1 transcripts (Figure 3B). Trans-
fection of control siRNA did not affect Notch-induced
extensions (Figure 3C). VEGFR-2 siRNA resulted in
only a modest decrease in the Notch-induced extensions
compared to its ability to suppress VEGF-A-induced
extensions (Figure 3C, D, G, H). However, transfection
Figure 1 Notch signaling induced cellular extensions and VEGFR-1 expression in HUVEC. HUVEC were transduced with either Ad-LacZ or
Ad-N1IC (MOI 40) and seeded on collagen type I gel for five days. Representative images from each cell culture are shown (10× magnification).
(A) Ad-LacZ HUVEC did not form extensions, (B) while Ad-N1IC HUVEC underwent morphological changes as seen by the sprouting of
extensions into the underlying matrix. (C) Morphological differentiation of Ad-N1IC HUVEC was not affected by the addition of 1 μM PD166866
(FGFR inhibitor), or (D) 1 μM ZD1893 (EGFR inhibitor). (E) The addition of 0.5 μM SU5416 (a VEGFR inhibitor), suppressed the morphological
differentiation of Ad-N1IC HUVEC. (F) Quantification of the effect of the different tyrosine kinase inhibitors on Notch-induced cellular extensions
and cell number. (G) Quantification of the effect of increasing amounts of the VEGFR inhibitor (SU5416) on Notch-induced cellular extensions
and cell number. For morphogenesis assays, HUVEC with sprouting extensions per 10× microscopy field were counted, for five separate fields.
Data is representative of the mean plus or minus SEM of three separate experiments, relative to control. Cell number was determined as percent
of control using colorimetric cell proliferation kit. (H) RT-PCR of RNA isolated from mock (X) or N1IC-expressing retrovirally transduced HUVEC
lines for VEGFR-1 (30 cycles), VEGFR-2 (30 cycles) and b-actin (25 cycles) (I) Western blot of total cell lysate from Ad-LacZ or Ad-N1IC transduced
HUVEC to detect VEGFR-1 protein expression. Detection of a-tubulin was used as a loading control.
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Figure 2 Notch1-induced HUVEC morphological changes were enhanced by the VEGFR-1-specific ligand PlGF. HUVEC were transduced
with Ad-LacZ or Ad-N1IC (MOI 40) and cultured on collagen type I gels in serum free medium with or without 50 ng/ml PlGF and evaluated for
the formation of cellular extensions. Representative images from each cell culture are shown (10× magnification). (A-B) Ad-LacZ HUVEC remained
a homogenous monolayer in the absence (NT) or presence of PlGF. (C) In the absence of PlGF, Ad-N1IC HUVEC undergo morphological
differentiation characterized by one or two extensions per cell (black arrowheads). (D) In presence of PlGF, there is an increase number of Ad-
N1IC HUVEC undergoing morphological changes and the number of extensions per cell (open arrowheads). (E) Quantification of total number of
Ad-N1IC HUVEC with cellular extensions and cells with multiple (>3) processes with or without PlGF. Number of cells with cellular extensions
were counted per 10× field, for five separate fields. Data is representative of the mean plus or minus SD of three separate experiments. * P <
0.01 compared with cultures without PlGF. (F) RT-PCR of RNA isolated from Ad-LacZ and Ad-N1IC HUVEC for VEGF-A (22 cycles), PlGF (25 cycles)
and GAPDH (22 cycles), as a control.
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of VEGFR-1 siRNA significantly reduced Notch-induced
extensions in HUVEC (Figure 3E). Quantification of
extensions in these cultures demonstrated that a lower
dose of VEGFR-1 siRNA resulted in a less dramatic
decrease in the number of extensions compared to con-
trol than a higher dose of VEGFR-1 siRNA (42% vs 21%
of control, respectively, Figure 3F). Because VEGFR-2
siRNA drastically reduced VEGF-A-induced extensions
(Figure 3H, I), but has only a modest affect on Notch-
induced extensions (Figure 3D, I), our results support
the possibility that Notch1 acts downstream of VEGF-
A/VEGFR-2 signaling and induces endothelial cell mor-
phogenesis via VEGFR-1.
Expression of VEGFR-1 in neovessels was decreased when
Notch signaling is inhibited
The role of Notch in physiological angiogenesis was
evaluated using a Dorsal Air Sac (DAS) assay, where a
chamber containing VEGF121-expressing pancreatic KP1
tumor cells (KP1/VEGF121) is implanted under the dor-
sal skin of a mouse and the overlying dermis evaluated
for ingrowth of vessels [31]. In this assay, we used a
protein-based inhibitor of Notch signaling that encodes
the extracellular EGF-like repeat domain of Notch1
fused to the human Fc domain, which we call the
‘Notch1 decoy’ [27]. We have shown that angiogenesis
is induced in the smooth muscle layer of the skin over-
lying the KP1/VEGF121 chamber, but is inhibited when
KP1/VEGF121 cells also express the Notch1 decoy via
adenoviral transduction (Ad-Notch1 decoy) as compared
to control (Ad-GFP) [27]. Thus, in this assay, VEGF121-
induced angiogenesis was dependent on Notch signaling
[27]. To evaluate endothelial VEGFR-1 and VEGFR-2
expression, cross sections of skin from the DAS assay
were immunostained with antibodies against VEGFR-1,
VEGFR-2 or CD31. Both VEGFR-1 and VEGFR-2 were
expressed in the neovessels of control KP1/VEGF121
implants transduced with Ad-GFP (Figure 4A-B).
VEGFR-2 staining was detected in implants transduced
with the Notch1 decoy, though its expression was
decreased, reflecting a decrease in vessel density (Figure
4C, black arrowheads). However, expression of VEGFR-
1 in Notch1 decoy-expressing implants was significantly
reduced compared to control, and seen only faintly in
the smooth muscle cell layer (Figure 4D, open arrow-
heads). To normalize for decreased vessel density in
implants expressing the Notch1 decoy, the intensity of
VEGFR-1 and VEGFR-2 signals was compared to that of
the endothelial cell marker CD31 by quantitative analy-
sis of immunohistochemical signal for each antibody
(Figure 4E). While VEGFR-2 expression was decreased
in the Notch1 decoy-expressing implant to the same
extent as CD31 (36% and 35% of Ad-GFP implants,
respectively), VEGFR-1 expression was decreased by a
greater extent than either VEGFR-2 or CD31 (14% of
Figure 3 Notch-induced sprouting in HUVEC did not depend
on VEGFR-2 expression. (A, B) Ad-N1IC HUVEC were transfected
with 200 pmol of control, VEGFR-1 or VEGFR-2 siRNA and cultured
on collagen gels. (A, upper panels) RT-PCR of Ad-N1IC HUVEC
transfected with control (CT), or VEGFR-1 siRNA for VEGFR-1 and
VEGFR-2 (25 cycles each) and (lower panels) western blot with an
antibody against VEGFR-1 demonstrated decreased transcript and
protein levels of VEGFR-1 in cells transfected with VEGFR-1 siRNA
relative. VEGFR-2 transcripts were unchanged by VEGFR-1 siRNA.
GAPDH (25 cycles) and a-tubulin were used as controls for the RT-
PCR and western blot, respectively. (B, upper panels) RT-PCR of Ad-
N1IC HUVEC transfected with control (CT) or VEGFR-2 siRNA for
VEGFR-1, VEGFR-2 and GAPDH (25 cycles each) and (lower panels)
western blot with an antibody against VEGFR-2. VEGFR-2 siRNA
suppressed VEGFR-2 transcripts and protein, but did not alter
VEGFR-1 transcripts. (C-E) Three days after transfection with control,
VEGFR-1 or VEGFR-2 siRNAs, Ad-N1IC HUVEC were evaluated for
morphological changes (compare cell extensions, black arrowheads).
Representative images are shown (10× magnification). (C) N1IC-
induced cellular extensions was unaffected by control siRNA. (D)
VEGFR-2 siRNA resulted in a modest decrease in Notch-induced
morphological changes. (E) VEGFR-1 siRNA suppressed the
morphological differentiation of Ad-N1IC HUVEC. (F) Quantification
of the effect of either 100 or 200 pmol VEGFR-1 siRNA on Notch-
induced HUVEC undergoing morphological changes. (G, H) Ad-
VEGF-A (VEGF) HUVEC were transfected with 200 pmol of control
(CT) or VEGFR-2 siRNA and cultured on collagen gels for three days.
(G) Ad-VEGF HUVEC underwent morphological changes with control
siRNA. (H) VEGFR-2 siRNA suppressed Ad-VEGF HUVEC
morphological changes. (I) Quantification of the effect of 200 pmol
VEGFR-2 siRNA on VEGF-A or Notch-induced morphological
changes. VEGFR-2 siRNA only modestly affected Ad-N1IC HUVEC
morphogenesis, while it strongly suppressed Ad-VEGF HUVEC
morphogenesis. (F, I) Cells with extensions were counted per 10×
field, for five separate fields. Data is representative of the mean plus
or minus SD of three separate experiments. * P < 0.01 compared
with control.
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control). This suggests that expression of the Notch1
decoy in KP1/VEGF121 cells reduced vessel number, but
not VEGFR-2 expression in endothelial cells, whereas
the decrease in VEGFR-1 expression was independent of
the decrease in vessel number. Thus, in VEGF-induced
neovascularization, VEGFR-1 expression is dependent
on Notch signaling.
This regulation was also found in cultured HUVEC,
where VEGF-A-induced expression of VEGFR-1 was
reduced by co-expression of the Notch1 decoy, as
shown by RT-PCR (Figure 4F). In contrast, induction of
VEGFR-2 by VEGF-A in HUVEC was unaffected by the
Notch1 decoy (Figure 4F). Similarly, VEGFR-1 expres-
sion on the surface of VEGF-A-treated HUVEC was
suppressed by treatment with a gamma secretase inhibi-
tor (GSI), Compound E, as analyzed by flow cytometry
(Figure 4G). Thus, two means of Notch inhibition were
used to establish that VEGF-A induces Notch signaling
which in turn regulates VEGFR-1 and that this regula-
tory pathway is active in both cultured endothelial cells
and neovessels in mice.
Discussion
Our results show that VEGFR-1 is downstream of
Notch1 signaling in endothelial cells. We identify a posi-
tive role for Notch signaling in endothelial morphogen-
esis via the induction of cellular extensions mediated by
VEGFR-1. Supporting this conclusion is the observation
that Notch increases VEGFR-1 levels and this increase
correlated with increased endothelial responsiveness to
the VEGFR-1-specific ligand, PlGF. Using a protein-
based Notch inhibitor, Notch1 decoy, or a gamma secre-
tase inhibitor, we demonstrate that perturbation of
endogenous Notch signaling resulted in reduced
VEGFR-1 expression. Thus, loss- and gain- of function
studies show that Notch signaling regulates VEGFR-1
expression in HUVEC and dermal neovessels.
Previous studies have demonstrated a role for the
Notch ligand, Dll4, in inhibiting a tip cell phenotype in
the developing vasculature of the retina [16,17]. In addi-
tion, Harrington et al [24] have shown that VEGFR-1 is
upregulated by Dll4, and demonstrated that Dll4 signal-
ing inhibited sprout length in a HUVEC tubulogenesis
assay. The authors suggest that Dll4 signaling inhibits
angiogenesis by inducing VEGFR-1 [24]. In summary,
previous studies have found a negative role for Notch
signaling in endothelial cell sprouting, and have focused
on this signaling pathway at the level of the ligand, Dll4.
However, in these studies, the Notch receptor responsi-
ble for these effects is not defined and the possibility of
divergent effects of different Notch receptors is not
addressed. By focusing on the effects of Notch signaling
at the level of the receptor, our results add new insights
to the role of Notch and VEGFR-1 in sprouting
angiogenesis. In contrast to previous studies, our data
suggest that in some settings, Notch signaling may play
a positive role in endothelial cell extension of filopodia-
like structures via its regulation of VEGFR-1 and sup-
ports a novel role Notch1-mediated regulation of
VEGFR-1 in endothelial cell morphogenesis.
It has recently been found that VEGFR-1 promotes
vascular sprout formation and branching morphogenesis
[35,36]. Kearney et al [35] propose that this results from
VEGFR-1 binding to VEGF-A, thereby regulating the
amount of VEGF-A that is available to interact with
VEGFR-2. They also show that soluble VEGFR-1
(sVEGFR-1) can promote sprout formation and migra-
tion. The positive effect of Notch signaling on HUVEC
sprouting that we report may therefore be due to its
effect on VEGFR-1, and subsequently, on local levels
and availability of VEGF-A. This may particularly be the
case if the predominant effect of Notch signaling is due
to regulation of sVEGFR-1. In general, the relative pro-
portion of the membrane bound and secreted isoform of
VEGFR-1 does not change significantly (data not shown,
and Kappas et al [36]), therefore, we cannot entirely
exclude the possibility that Notch-induced sprouting in
HUVEC is due to sequestration of VEGF-A. However,
we show that Notch-induced sprouting in HUVEC is
enhanced in the presence of PlGF, a VEGFR-1 specific
ligand, suggesting that signaling through the VEGFR-1
receptor itself, and not simply its function as a ‘VEGF-A
sink,’ may be responsible for Notch-mediated sprouting.
This is further supported by the fact that VEGFR-1
siRNA inhibited Notch-induced sprouting in HUVEC
while VEGFR-2 siRNA had only a modest effect. Thus,
our data support the conclusion that activation of Notch
signaling in HUVEC can induce extensions via VEGFR-
1, and highlight the possibility that Notch signaling may
act through VEGFR-1 to have a positive effect on
endothelial cell morphogenesis.
It has been reported that inhibition of VEGFR-1 in the
developing retina does not effect sprouting and filopodia
extensions in endothelial cells [3,16]. In the retina,
endothelial tip cell filopodia are guided by a gradient of
VEGF-A provided by a template of astrocytes [3,37].
However, in our model of in vitro sprouting in HUVEC,
as well as in many in vivo settings of physiological and
pathological angiogenesis, the source of VEGF-A is
likely to be more diffuse. Notch-mediated sprouting via
regulation of VEGFR-1 may constitute a mechanism for
endothelial cell morphogenesis that is important in set-
tings where Notch1 is highly expressed in the vascula-
ture and where expression of VEGF-A is more global,
and endothelial cell sprouting less controlled, than in
formation of the retinal plexus. In addition, our finding
that Notch-induced sprouting in endothelial cells is
enhanced by PlGF may be relevant in angiogenic
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Figure 4 Inhibition of Notch signaling decreased VEGFR-1 expression in neovessels. Chambers packed with VEGF-expressing KP1
pancreatic tumor cells (KP1/VEGF-A121) transduced with either Ad-GFP or Ad-Notch1 decoy were implanted under the dorsal skin of wild-type
C57BL/6 mice. Four days after implantation, chambers were removed for immunohistochemistry of the overlying skin. Representative pictures are
shown (20× magnification). (A-B) VEGFR-1 and VEGFR-2 expression in the smooth muscle cell layer of the skin overlying implants expressing Ad-
GFP. (C) Expression of VEGFR-2 was detected in implants expressing the Notch1 decoy despite decreased vessel density (black arrowheads). (D)
Expression of VEGFR-1 in implants expressing the Notch1 decoy was significantly reduced in the smooth muscle cell layer (open arrowheads). (E)
Reduced VEGFR-1 expression relative to CD31 and VEGFR-2 was observed in skin overlying implants expressing the Notch1 decoy compared to
those expressing Ad-GFP. Quantitative analysis of immunostaining intensity for each antibody, relative to Ad-GFP implants (set at 100%), was
determined in five different areas of each sample. The average density ratio was determined by dividing the area of staining by the total area of
the smooth muscle layer. Each group (Ad-GFP versus Ad-Notch1 decoy) consisted of 3-5 mice, and experiments were done in triplicate. Data
represents the mean staining intensity in Notch1 decoy implants, expressed as percent of control staining, plus or minus SD. ⋆ P < 0.05. (F)
Notch1 decoy expression in HUVEC reduced VEGF-induced VEGFR-1 expression. Adenovirus transduction of VEGF-A in HUVEC increased the
expression of VEGFR-1 and VEGFR-2 as determined by RT-PCR (25 cycles) compared to control (Ad-LacZ) cells. When Ad-VEGF-A (VEGF) HUVEC
were co-transduced with the Notch1 decoy, transcript levels of VEGFR-1 were reduced, while VEGFR-2 was unaffected. (G) Gamma secretase
inhibitor (GSI) reduces VEGF-induced surface expression of VEGFR-1 in HUVEC. Stimulation of HUVEC with 50 ng/ml VEGF-A induced surface
expression of VEGFR-1 (red) compared to control cells (black). Co-incubation with GSI (Compound E) inhibited the VEGF-A-induction of VEGFR-1
(green). 10,000 cells per experimental group were examined by FACs.
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settings where PlGF is a major angiogenic factor. Since
PlGF is upregulated in pathological conditions by var-
ious stimuli [38-40], and contributes to the angiogenic
switch in various pathologies [6,41,42], Notch-mediated
upregulation of VEGFR-1 may prove an important step
in disease progression in these contexts. Furthermore,
our finding that blockade of Notch signaling using a
protein-based inhibitor of Notch1 (Notch1 decoy)
resulted in decreased expression of VEGFR-1 in an in
vivo model of angiogenesis may have important implica-
tions for the efficacy of inhibition of Notch signaling in
settings where VEGFR-1 expression is prominent, such
as in certain tumor types and in the initiation of preme-
tastatic niches [43-45].
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